AstraZeneca Hong Kong oversees both the Hong Kong and Macau markets and attaches a strong importance to them. Since its inception in 1990, AstraZeneca Hong Kong has delivered many life-changing medicines that have transformed the lives of patients and have revolutionized disease treatment in Hong Kong and Macau. Over the years, we have been continually expanding our business in order to meet the growing demand of the markets.
2020 is a momentous year for AstraZeneca Hong Kong as we celebrate the 30th anniversary of the establishment in Hong Kong. Our past achievements and the aspiration of continue focus on innovative science and leadership in our three main therapy areas could be summarized by the tagline - ‘Leading the future of Healthcare together. 30 years of Innovation’.
Underpinned by strong science and innovation in our Global R&D Centre and Corporate Headquarters in Cambridge. AstraZeneca Hong Kong focused on returning to growth through a science-led innovation strategy. We actively respond to the increasingly complex disease environment and the emerge of new health challenging by focusing on growth through innovation – embracing technology, digital and data to deliver patient-centric solutions to Hong Kong patients. We have played an active role in changing the healthcare environment in Hong Kong. Throughout our 30-year history, we have launched more than 100 products, including blockbusters, conducting over 100 clinical studies, including 30 breakthrough studies, and treating over 5,000,000 patients.
As a trusted healthcare partner, AstraZeneca Hong Kong have collaborated with over 95 Hong Kong sites and have supported local life science start-ups through training and mentoring to make life-changing discoveries. We are also a responsible corporate citizen of the society. To ensure our medicines are accessible, AstraZeneca Hong Kong has provided different Patient Affordability Programs to cancer patients in collaboration with local associations in the past years. We are also working with different non-governmental organizations (NGOs) to provide patient empowerment programs in Respiratory, Diabetes, Cardiovascular and Cancer diseases.
Our strategic priorities are to deliver growth and TA leadership, accelerate innovative science and be a great place to work. As we celebrate our past accomplishments, we are confident about the future– because of our people, our partners and our firm commitment to pushing the boundaries of science to deliver life-changing medicines. Looking ahead, we will continue focus on sustainable development and the delivery of a flow of new medicines that make a difference in the lives of patients in Hong Kong and around the world.
For more information about AstraZeneca, please go to: www.astrazeneca.com.